Skip to main content

Advertisement

SpringerLink
Log in

Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Syndecan-1 has been implicated in tumorigenesis and progression of various human malignancies. Recent studies have demonstrated that syndecan-1 may have a different function and biological activity depending on the specific tumor type. Therefore, the aim of this study was to investigate the clinical significance of syndecan-1 in human gliomas. One hundred and sixteen glioma patients (26 World Health Organization (WHO) grade I, 30 WHO grade II, 30 WHO grade III, and 30 WHO grade IV) and 15 normal brain specimens acquired from 15 patients undergoing surgery for epilepsy as control were collected. Immunohistochemistry assay, quantitative real-time PCR and Western blot analysis were carried out to detect the expression of syndecan-1 at gene and protein levels in glioma samples with different WHO grades. Syndecan-1 gene and protein levels were both higher in glioma tissues compared to controls (both P < 0.001). In addition, its expression levels increased with ascending tumor WHO grades according to the results of immunohistochemistry assay, quantitative real-time PCR and Western blot analysis. Moreover, the survival rate of syndecan-1-positive patients was significantly lower than that of syndecan-1-negative patients (P = 0.006). We further confirmed that the increased expression of syndecan-1 was an independent prognostic indicator in glioma by multivariate analysis (P = 0.01). Our data suggest for the first time that the increased expression of syndecan-1 at gene and protein levels is correlated with advanced tumor progression and poor outcome in patients with glioma. Syndecan-1 might serve as a potential prognosis predictor of this dismal tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ohgaki H, Kleihues P (2005) Epidemiology and etiology of gliomas. Acta Neuropathol 109:93

    Article  PubMed  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD (2007) The 2007 WHO classifcation of tumors of the central nervous system. Acta Neuropathol 114:97–109

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zhang X, Yang H, Gong B, Jiang C, Yang L (2012) Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis. J Neurooncol 107:281–288

    Article  CAS  PubMed  Google Scholar 

  4. Curran WJ Jr, Scott CB (1996) Radiosurgery for glioma patients: hope or hype? Int J Radiat Oncol Biol Phys 36:1279–1280

    Article  PubMed  Google Scholar 

  5. Teoh-Fitzgerald ML, Fitzgerald MP, Jensen TJ, Futscher BW, Domann FE (2012) Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis. Mol Cancer Res 10:40–51

    Article  CAS  PubMed  Google Scholar 

  6. Rousseau C, Ruellan AL, Bernardeau K, Kraeber-Bodéré F, Gouard S, Loussouarn D, Saï-Maurel C, Faivre-Chauvet A, Wijdenes J, Barbet J, Gaschet J, Chérel M, Davodeau F (2011) Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res 1:20

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lendorf ME, Manon-Jensen T, Kronqvist P, Multhaupt HA, Couchman JR (2011) Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 59:615–629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Beauvais DM, Rapraeger AC (2010) Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 123:3796–3807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bologna-Molina R, González-González R, Mosqueda-Taylor A, Molina-Frechero N, Damián-Matsumura P, Dominguez-Malagón H (2010) Expression of syndecan-1 in papillary carcinoma of the thyroid with extracapsular invasion. Arch Med Res 41:33–37

    Article  CAS  PubMed  Google Scholar 

  10. Kim H, Choi DS, Chang SJ, Han JH, Min CK, Chang KH, Ryu HS (2010) The expression of syndecan-1 is related to the risk of endometrial hyperplasia progressing to endometrial carcinoma. J Gynecol Oncol 21:50–55

    Article  PubMed  PubMed Central  Google Scholar 

  11. Charni F, Friand V, Haddad O, Hlawaty H, Martin L, Vassy R, Oudar O, Gattegno L, Charnaux N, Sutton A (2009) Syndecan-1 and syndecan-4 are involved in RANTES/CCL5-induced migration and invasion of human hepatoma cells. Biochim Biophys Acta 1790:1314–1326

    Article  CAS  PubMed  Google Scholar 

  12. Ishikawa T, Kramer RH (2010) Sdc1 negatively modulates carcinoma cell motility and invasion. Exp Cell Res 316:951–965

    Article  CAS  PubMed  Google Scholar 

  13. Metwaly HA, Al-Gayyar MM, Eletreby S, Ebrahim MA, El-Shishtawy MM (2012) Relevance of serum levels of interleukin-6 and syndecan-1 in patients with hepatocellular carcinoma. Sci Pharm 80:179–188

    Article  CAS  PubMed  Google Scholar 

  14. Yang N, Mosher R, Seo S, Beebe D, Friedl A (2011) Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am J Pathol 178:325–335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, Fujimoto K, Hirao K, Konishi N (2010) Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci 101:155–160

    Article  CAS  PubMed  Google Scholar 

  16. Wang H, Si JL, Zhang XZ, Qi YQ, Niu ZY, Zhou CH (2010) Expression and clinical significance of syndecan-1 mRNA and HPA-1 mRNA in colorectal cancer detected with real-time fluorescent quantitative polymerase chain reaction. Chin J Cancer 29:288–293

    Article  PubMed  Google Scholar 

  17. Stepp MA, Pal-Ghosh S, Tadvalkar G, Rajjoub L, Jurjus RA, Gerdes M, Ryscavage A, Cataisson C, Shukla A, Yuspa SH (2010) Loss of syndecan-1 is associated with malignant conversion in skin carcinogenesis. Mol Carcinog 49:363–373

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Naganuma H, Satoh E, Asahara T, Amagasaki K, Watanabe A, Satoh H, Kuroda K, Zhang L, Nukui H (2004) Quantification of thrombospondin-1 secretion and expression of alphavbeta3 and alpha3beta1 integrins and syndecan-1 as cell-surface receptors for thrombospondin-1 in malignant glioma cells. J Neurooncol 70:309–317

    Article  PubMed  Google Scholar 

  19. Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, Naganuma H (2006) Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J Neurooncol 77:25–32

    Article  CAS  PubMed  Google Scholar 

  20. Roh YH, Kim YH, Choi HJ, Lee KE, Roh MS (2008) Syndecan-1 expression in gallbladder cancer and its prognostic significance. Eur Surg Res 41:245–250

    Article  CAS  PubMed  Google Scholar 

  21. Stetler-Stevenson WG, Kleiner DE Jr (2001) Molecular biology of cancer: invasion and metastases. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams and Willkins, Philadelphia7, pp 123–136

    Google Scholar 

  22. Sanderson RD, Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25:149–159

    Article  CAS  PubMed  Google Scholar 

  23. Lofgren L, Sahlin L, Jiang S, Von Schoultz B, Fernstad R, Skoog L, Von Schoultz E (2007) Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 27:3045–3050

    CAS  PubMed  Google Scholar 

  24. Mukunyadzi P, Sanderson RD, Fan CY, Smoller BR (2002) The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol 15:45–49

    Article  PubMed  Google Scholar 

  25. Rintala M, Inki P, Klemi P, Jalkanen M, Grénman S (1999) Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Gynecol Oncol 75:372–378

    Article  CAS  PubMed  Google Scholar 

  26. Shah L, Walter KL, Borczuk AC, Kawut SM, Sonett JR, Gorenstein LA, Ginsburg ME, Steinglass KM, Powell CA (2004) Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer 101:1632–1638

    Article  CAS  PubMed  Google Scholar 

  27. Gökden N, Greene GF, Bayer-Garner IB, Spencer HJ, Sanderson RD, Gökden M (2006) Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Appl Immunohistochem Mol Morphol 14:173–177

    Article  PubMed  Google Scholar 

  28. Chen CL, Ou DL (2006) Expression of syndecan-1 (CD138) in nasopharyngeal carcinoma is correlated with advanced stage and poor prognosis. Hum Pathol 37:1279–1285

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, First Affiliated Hospital of Medical College, Shantou University, Shantou, 515041, Guangdong Province, China

    Yimin Xu, Jun Yuan, Ziheng Zhang, Lvbiao Lin & Shengliang Xu

Authors
  1. Yimin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ziheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lvbiao Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shengliang Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Yuan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, Y., Yuan, J., Zhang, Z. et al. Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis. Mol Biol Rep 39, 8979–8985 (2012). https://doi.org/10.1007/s11033-012-1767-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-012-1767-9

Keywords

Search

Navigation